Pharmacokinetic profile of fosfomycin trometamol

Chemotherapy. 1993 Sep-Oct;39(5):297-301. doi: 10.1159/000239140.


The pharmacokinetics of fosfomycin trometamol has been assessed in 12 healthy volunteers given oral doses of 2, 3, and 4 g of fosfomycin and 3 g intravenously of fosfomycin as fosfomycin sodium, all in the fasting state. The assay was microbiological (Proteus mirabilis ATCC 21100). There was a gradual rise in both peak serum concentrations and total area under the curve by rising oral doses, from 16.0 mg/l and 106.7 mg x h/l, after 2 g to 30.9 mg/l and 189.7 mg x h/l after 4 g respectively. The serum half-life was 4 h after the oral doses and 2.1 h after the intravenous dose. After the oral doses, the amounts excreted in urine in the active form ranged from 36 to 40% compared to 93% after the intravenous dose. The bioavailability was slightly below 40%. Concentrations in urine covers the usual urinary tract pathogens after oral doses of 2, 3, and 4 g.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adult
  • Biological Availability
  • Female
  • Fosfomycin / blood
  • Fosfomycin / pharmacokinetics*
  • Fosfomycin / urine
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Male
  • Metabolic Clearance Rate


  • Fosfomycin